<p>Sagimet Biosciences Inc.（纳斯达克股票代码：SGMT - 获取免费报告）在 7 月份看到了空头头寸显著下降。截至 7 月 15 日，空头头寸总计 1,670,000 股，较 6 月 30 日的 2,280,000 股减少了 26.8%。目前，该股的 8.0% 股份被空头卖空。基于平均每日交易量为 536,900 股，目前的空头头寸比率为 3.1 天。</p>
<p>获取 <strong>Sagimet Biosciences</strong> 警报：</p>
<h2>Sagimet Biosciences 股票表现</h2>
<p>纳斯达克股票代码：SGMT 周五午盘交易中上涨$0.02，达到$3.42。该股交易量为 239,160 股，低于其平均交易量 542,058 股。该公司的 50 天移动平均价格为$4.04，200 天移动平均价格为$5.52。Sagimet Biosciences 过去 12 个月的最低价为$2.13，最高价为$20.71。</p>
<p>Sagimet Biosciences（纳斯达克股票代码：SGMT - 获取免费报告）上次公布季度财报是在 5 月 15 日星期三。公司报告该季度每股亏损 ($0.23)，超过了每股 ($0.41) 的共识预期$0.18。股票研究分析师预计，Sagimet Biosciences 今年将实现-1.76 美元的每股盈利。</p>
<h2>内部人员的买卖行为</h2>
<p>据相关消息，董事长 George Kemble 于 7 月 19 日星期五以每股$3.10 的均价出售了公司 14,062 股股票。此次交易总价值为$43,592.20。交易完成后，董事长在公司拥有 142,318 股股份，价值$441,185.80。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。另外，Sagimet Biosciences 内部人员 Eduardo Bruno Martins 于 7 月 19 日星期五以每股$3.10 的均价出售了 8,357 股 Sagimet Biosciences 股票。此次交易总价值为$25,906.70。交易完成后，该内部人员在公司拥有 81,213 股股份，价值$251,760.30。该交易已在提交给 SEC 的文件中披露，可通过此超链接访问。此外，董事长 George Kemble 于 7 月 19 日星期五以每股$3.10 的均价出售了 14,062 股 Sagimet Biosciences 股票。这些股票的总价值为$43,592.20。交易完成后，董事长在公司拥有 142,318 股股份，价值约为$441,185.80。此次交易的披露信息可在此处找到。过去一个季度，内部人员已经出售了价值$178,224 的公司股票共 56,958 股。公司内部人员拥有公司股份的 17.60%。</p>
<h2>对 Sagimet Biosciences 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。ORG Partners LLC 在第二季度收购了 Sagimet Biosciences 股票的新头寸，价值约$43,000。DekaBank Deutsche Girozentrale 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$113,000。Ikarian Capital LLC 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$2,236,000。Price T Rowe Associates Inc. MD 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$91,000。最后，美国国际集团在第一季度增加了其对 Sagimet Biosciences 股票的持股，持股量增加了 312.0%。美国国际集团现在拥有公司股份 11,372 股，价值$62,000，在此期间增加了 8,612 股。公司股份的 87.86% 归机构投资者和对冲基金所有。</p>
<h2>华尔街分析师预测增长</h2>
<p>许多研究分析师已经发布了关于该公司的报告。高盛集团重申了对 Sagimet Biosciences 的&#34;中性&#34;评级，并在 6 月 28 日星期五的研究报告中发布了$6.00 的目标股价（之前为$23.00）。JMP 证券重申了对 Sagimet Biosciences 的&#34;市场表现优异&#34;评级，并在 6 月 7 日星期五的研究报告中发布了$48.00 的目标股价。最后，HC Wainwright 重申了对 Sagimet Biosciences 的&#34;买入&#34;评级，并在 6 月 14 日星期五的研究报告中发布了$32.00 的目标股价。一位分析师给予该股&#34;持有&#34;评级，而其他六位分析师给予该公司股票&#34;买入&#34;评级。根据 MarketBeat.com 的数据，Sagimet Biosciences 目前的共识评级为&#34;中等买入&#34;，目标股价为$35.80。</p>
<p><strong>阅读我们关于 SGMT 的最新研究报告</strong></p>
<h2>Sagimet Biosciences 公司简介（获取免费报告）</h2>
<p>Sagimet Biosciences Inc 是一家临床阶段的生物制药公司，致力于开发称为脂肪酸合酶（FASN）抑制剂的治疗药物，用于治疗因代谢途径功能失调而导致的疾病。该公司的主力药物候选者是 Denifanstat，一种每日一次的药丸和选择性 FASN 抑制剂，用于治疗与代谢功能障碍相关的脂肪肝。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们喜欢的股票，比 Sagimet Biosciences 更好</li>
<li>提供高股息收益的 3 只天然气股票</li>
<li>为什么这 2 只股票的认购期权交易量会同时激增</li>
<li>如何投资 FAANG 股票</li>
<li>MarketBeat 周评 - 7/22 - 7/26</li>
<li>投资组合增长的 3 家最佳金融科技股</li>
<li>3M 惊喜和复苏加速：现在加入还不算晚</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 我对人工智能股票的严峻警告（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3"/></p>
<h2>你现在是否应该投资$1,000 到 Sagimet Biosciences？</h2>
<p>在考虑投资 Sagimet Biosciences 之前，您可能需要听听这个消息。</p>
<p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而 Sagimet Biosciences 并不在这个名单上。</p>
<p>尽管 Sagimet Biosciences 目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SGMT

<p>Sagimet Biosciences Inc.（纳斯达克股票代码：SGMT）在 7 月份看到空头头寸下降了 26.8%，卖空 1,670,000 股。目前的空头头寸比率为 3.1 天。该公司股票目前交易价格为$3.42，50 天移动平均价格为$4.04。内部人士已经卖出 56,958 股价值$178,224 的公司股票。分析师给予该股票 “中等买入” 评级，目标价格为$35.80</p>

<p>Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 1,670,000 shares, a drop of 26.8% from the June 30th total of 2,280,000 shares. Currently, 8.0% of the shares of the stock are short sold. Based on an average daily volume of 536,900 shares, the short-interest ratio is currently 3.1 days.</p>
<div class="lb-trans"><p>Sagimet Biosciences Inc.（纳斯达克股票代码：SGMT - 获取免费报告）在 7 月份看到了空头头寸显著下降。截至 7 月 15 日，空头头寸总计 1,670,000 股，较 6 月 30 日的 2,280,000 股减少了 26.8%。目前，该股的 8.0% 股份被空头卖空。基于平均每日交易量为 536,900 股，目前的空头头寸比率为 3.1 天。</p>
</div><p>Get <strong>Sagimet Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sagimet Biosciences</strong> 警报：</p>
</div><h2>Sagimet Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Sagimet Biosciences 股票表现</h2>
</div><p>Shares of NASDAQ:SGMT traded up $0.02 during midday trading on Friday, hitting $3.42. 239,160 shares of the stock were exchanged, compared to its average volume of 542,058. The business's 50-day moving average price is $4.04 and its 200 day moving average price is $5.52. Sagimet Biosciences has a 12 month low of $2.13 and a 12 month high of $20.71.</p>
<div class="lb-trans"><p>纳斯达克股票代码：SGMT 周五午盘交易中上涨$0.02，达到$3.42。该股交易量为 239,160 股，低于其平均交易量 542,058 股。该公司的 50 天移动平均价格为$4.04，200 天移动平均价格为$5.52。Sagimet Biosciences 过去 12 个月的最低价为$2.13，最高价为$20.71。</p>
</div><p>Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.18. Equities research analysts anticipate that Sagimet Biosciences will post -1.76 earnings per share for the current year.</p>
<div class="lb-trans"><p>Sagimet Biosciences（纳斯达克股票代码：SGMT - 获取免费报告）上次公布季度财报是在 5 月 15 日星期三。公司报告该季度每股亏损 ($0.23)，超过了每股 ($0.41) 的共识预期$0.18。股票研究分析师预计，Sagimet Biosciences 今年将实现-1.76 美元的每股盈利。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员的买卖行为</h2>
</div><p>In related news, Chairman George Kemble sold 14,062 shares of the firm's stock in a transaction on Friday, July 19th. The stock was sold at an average price of $3.10, for a total value of $43,592.20. Following the transaction, the chairman now owns 142,318 shares in the company, valued at $441,185.80. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. In other Sagimet Biosciences news, insider Eduardo Bruno Martins sold 8,357 shares of Sagimet Biosciences stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $3.10, for a total value of $25,906.70. Following the transaction, the insider now owns 81,213 shares in the company, valued at $251,760.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman George Kemble sold 14,062 shares of Sagimet Biosciences stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $3.10, for a total value of $43,592.20. Following the completion of the transaction, the chairman now owns 142,318 shares in the company, valued at approximately $441,185.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,958 shares of company stock worth $178,224. Company insiders own 17.60% of the company's stock.</p>
<div class="lb-trans"><p>据相关消息，董事长 George Kemble 于 7 月 19 日星期五以每股$3.10 的均价出售了公司 14,062 股股票。此次交易总价值为$43,592.20。交易完成后，董事长在公司拥有 142,318 股股份，价值$441,185.80。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。另外，Sagimet Biosciences 内部人员 Eduardo Bruno Martins 于 7 月 19 日星期五以每股$3.10 的均价出售了 8,357 股 Sagimet Biosciences 股票。此次交易总价值为$25,906.70。交易完成后，该内部人员在公司拥有 81,213 股股份，价值$251,760.30。该交易已在提交给 SEC 的文件中披露，可通过此超链接访问。此外，董事长 George Kemble 于 7 月 19 日星期五以每股$3.10 的均价出售了 14,062 股 Sagimet Biosciences 股票。这些股票的总价值为$43,592.20。交易完成后，董事长在公司拥有 142,318 股股份，价值约为$441,185.80。此次交易的披露信息可在此处找到。过去一个季度，内部人员已经出售了价值$178,224 的公司股票共 56,958 股。公司内部人员拥有公司股份的 17.60%。</p>
</div><h2>Hedge Funds Weigh In On Sagimet Biosciences</h2>
<div class="lb-trans"><h2>对 Sagimet Biosciences 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ORG Partners LLC acquired a new position in shares of Sagimet Biosciences in the second quarter worth approximately $43,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $113,000. Ikarian Capital LLC acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $2,236,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $91,000. Finally, American International Group Inc. lifted its stake in shares of Sagimet Biosciences by 312.0% in the first quarter. American International Group Inc. now owns 11,372 shares of the company's stock worth $62,000 after acquiring an additional 8,612 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。ORG Partners LLC 在第二季度收购了 Sagimet Biosciences 股票的新头寸，价值约$43,000。DekaBank Deutsche Girozentrale 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$113,000。Ikarian Capital LLC 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$2,236,000。Price T Rowe Associates Inc. MD 在第一季度收购了 Sagimet Biosciences 股票的新头寸，价值约$91,000。最后，美国国际集团在第一季度增加了其对 Sagimet Biosciences 股票的持股，持股量增加了 312.0%。美国国际集团现在拥有公司股份 11,372 股，价值$62,000，在此期间增加了 8,612 股。公司股份的 87.86% 归机构投资者和对冲基金所有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have issued reports on the company. The Goldman Sachs Group reiterated a &#34;neutral&#34; rating and issued a $6.00 target price (down previously from $23.00) on shares of Sagimet Biosciences in a research report on Friday, June 28th. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $48.00 target price on shares of Sagimet Biosciences in a research report on Friday, June 7th. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $32.00 target price on shares of Sagimet Biosciences in a research report on Friday, June 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Sagimet Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $35.80.</p>
<div class="lb-trans"><p>许多研究分析师已经发布了关于该公司的报告。高盛集团重申了对 Sagimet Biosciences 的&#34;中性&#34;评级，并在 6 月 28 日星期五的研究报告中发布了$6.00 的目标股价（之前为$23.00）。JMP 证券重申了对 Sagimet Biosciences 的&#34;市场表现优异&#34;评级，并在 6 月 7 日星期五的研究报告中发布了$48.00 的目标股价。最后，HC Wainwright 重申了对 Sagimet Biosciences 的&#34;买入&#34;评级，并在 6 月 14 日星期五的研究报告中发布了$32.00 的目标股价。一位分析师给予该股&#34;持有&#34;评级，而其他六位分析师给予该公司股票&#34;买入&#34;评级。根据 MarketBeat.com 的数据，Sagimet Biosciences 目前的共识评级为&#34;中等买入&#34;，目标股价为$35.80。</p>
</div><p><strong>Read Our Latest Research Report on SGMT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 SGMT 的最新研究报告</strong></p>
</div><h2>Sagimet Biosciences Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Sagimet Biosciences 公司简介（获取免费报告）</h2>
</div><p>Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.</p>
<div class="lb-trans"><p>Sagimet Biosciences Inc 是一家临床阶段的生物制药公司，致力于开发称为脂肪酸合酶（FASN）抑制剂的治疗药物，用于治疗因代谢途径功能失调而导致的疾病。该公司的主力药物候选者是 Denifanstat，一种每日一次的药丸和选择性 FASN 抑制剂，用于治疗与代谢功能障碍相关的脂肪肝。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Sagimet Biosciences</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Why Call Options Volume for These 2 Stocks Spiked Together</li>
<li>How to Invest in the FAANG Stocks</li>
<li>MarketBeat Week in Review – 7/22 - 7/26</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们喜欢的股票，比 Sagimet Biosciences 更好</li>
<li>提供高股息收益的 3 只天然气股票</li>
<li>为什么这 2 只股票的认购期权交易量会同时激增</li>
<li>如何投资 FAANG 股票</li>
<li>MarketBeat 周评 - 7/22 - 7/26</li>
<li>投资组合增长的 3 家最佳金融科技股</li>
<li>3M 惊喜和复苏加速：现在加入还不算晚</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ My grim warning about AI stocks (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我对人工智能股票的严峻警告（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8717&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sagimet Biosciences right now?</h2>
<div class="lb-trans"><h2>你现在是否应该投资$1,000 到 Sagimet Biosciences？</h2>
</div><p>Before you consider Sagimet Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Sagimet Biosciences 之前，您可能需要听听这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而 Sagimet Biosciences 并不在这个名单上。</p>
</div><p>While Sagimet Biosciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Sagimet Biosciences 目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sagimet Biosciences Inc.（纳斯达克股票代码：SGMT）7 月份的空头头寸下降了 26.8%